Benthe Muntinghe

Benthe Muntinghe is a medical researcher specializing in non-small cell lung cancer (NSCLC) with active contributions to oncology research between 2022-2025. Her work shows strong collaboration with University Medical Center Groningen researchers, particularly in the fields of immunotherapy and diagnostic innovation.

Her research focuses on critical areas of lung cancer treatment including CD8+ T cell activation as a predictor of treatment response, combination therapies involving stereotactic radiotherapy with immune checkpoint inhibitors (durvalumab and tremelimumab), and innovative diagnostic approaches using electronic nose technology for non-invasive lung cancer detection. Her work addresses key challenges in NSCLC treatment personalization and response prediction.

Analysis of her publication record reveals a strong emphasis on translational research bridging laboratory findings with clinical applications, particularly in identifying biomarkers for treatment response and developing novel combination therapies. Her work spans diagnostic innovation, therapeutic optimization, and clinical trial design in advanced NSCLC.

Her research contributes significantly to UN Sustainable Development Goals related to good health and well-being, particularly through advancements in cancer diagnostics and treatment personalization.

Muntinghe's collaborative network demonstrates extensive work with clinical oncology teams, focusing on practical applications of immunotherapy and radiotherapy combinations. Her research trajectory indicates growing involvement in multi-center clinical trials and diagnostic validation studies.